Your browser doesn't support javascript.
loading
Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.
Weber, Jeffrey S; Poretta, Tayla; Stwalley, Brian D; Sakkal, Leon A; Du, Ella X; Wang, Travis; Chen, Yan; Wang, Yan; Betts, Keith A; Shoushtari, Alexander N.
  • Weber JS; Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA. jeffrey.weber@nyulangone.org.
  • Poretta T; Bristol Myers Squibb, Princeton, NJ, USA.
  • Stwalley BD; Bristol Myers Squibb, Princeton, NJ, USA.
  • Sakkal LA; Bristol Myers Squibb, Princeton, NJ, USA.
  • Du EX; Analysis Group, Inc., Los Angeles, CA, USA.
  • Wang T; Analysis Group, Inc., Los Angeles, CA, USA.
  • Chen Y; Analysis Group, Inc., Los Angeles, CA, USA.
  • Wang Y; Analysis Group, Inc., Los Angeles, CA, USA.
  • Betts KA; Analysis Group, Inc., Los Angeles, CA, USA.
  • Shoushtari AN; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Cancer Immunol Immunother ; 72(4): 945-954, 2023 Apr.
Article en En | MEDLINE | ID: mdl-36197494
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Melanoma Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Melanoma Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article